Janus Henderson Group PLC Raises Position in Olema Pharmaceuticals, Inc. $OLMA

Janus Henderson Group PLC lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 5.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,108,488 shares of the company’s stock after acquiring an additional 398,294 shares during the quarter. Janus Henderson Group PLC owned 0.08% of Olema Pharmaceuticals worth $106,013,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its holdings in Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new position in Olema Pharmaceuticals during the 4th quarter worth approximately $44,000. Russell Investments Group Ltd. acquired a new position in Olema Pharmaceuticals during the 3rd quarter worth approximately $53,000. American Century Companies Inc. purchased a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $54,000. Finally, Creative Planning purchased a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $83,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OLMA has been the subject of several recent analyst reports. Guggenheim reduced their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen cut shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.10.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the firm’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares in the company, valued at $8,282,826.60. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 12.56% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ:OLMA opened at $11.45 on Friday. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.67 and a beta of 2.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The business’s 50 day simple moving average is $11.42 and its 200-day simple moving average is $16.54. Olema Pharmaceuticals, Inc. has a 12 month low of $4.47 and a 12 month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). As a group, equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.